{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:02:52Z","timestamp":1792800172026,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009440","name":"DMG Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Proton pump inhibitors (PPIs) are commonly prescribed for laryngopharyngeal reflux (LPR), but their efficacy remains debated. Alginates is an option for the treatment of LPR with few adverse effects. The study aimed to investigate the non-inferiority of an alginate suspension (<jats:italic>Gastrotuss<\/jats:italic><jats:sup>\u00ae<\/jats:sup>) compared to PPIs (Omeprazole) in reducing LPR symptoms and signs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A non-inferiority randomized controlled trial was conducted. Fifty patients with laryngopharyngeal symptoms (Reflux Symptom Index -RSI-\u2009\u2265\u200913) and signs (Reflux Finding Score -RFS-\u2009\u2265\u20097) were randomized in two treatment groups: (A) <jats:italic>Gastrotuss<\/jats:italic><jats:sup><jats:italic>\u00ae<\/jats:italic><\/jats:sup> (20\u00a0ml, three daily doses) and, (B) Omeprazole (20\u00a0mg, once daily). The RSI and the RFS were assessed at baseline and after 2\u00a0months of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p><jats:bold>Groups had similar<\/jats:bold> RSI and RFS scores at baseline. From pre- to 2-month posttreatment, the mean RSI significantly decreased (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) in alginate and PPI group (<jats:italic>p<\/jats:italic>\u2009=\u20090.003). The difference between groups in the RSI change was not significant (95%CI: \u00a0\u2212\u00a04.2\u20136.7, <jats:italic>p<\/jats:italic>\u2009=\u20090.639). The mean RFS significantly decreased in alginate (<jats:italic>p<\/jats:italic>\u2009=\u20090.006) and PPI groups (<jats:italic>p<\/jats:italic>\u2009=\u20090.006). The difference between groups in the mean change RFS was not significant (95%CI: \u00a0\u2212\u00a00.8; 1.4, <jats:italic>p<\/jats:italic>\u2009=\u20090.608).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>After 2\u00a0months of treatment, LPR symptoms and signs are significantly reduced irrespective of the treatment. A<jats:italic>lginate<\/jats:italic> was non-inferior to PPIs and may represent an alternative treatment to PPIs for the treatment of LPR.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00405-021-07219-0","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T07:02:40Z","timestamp":1642230160000},"page":"2533-2542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Magnesium alginate versus proton pump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial"],"prefix":"10.1007","volume":"279","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3939-0742","authenticated-orcid":false,"given":"Nicole","family":"Pizzorni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-011X","authenticated-orcid":false,"given":"Federico","family":"Ambrogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Eplite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibora","family":"Rama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Robotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0845-0845","authenticated-orcid":false,"given":"Jerome","family":"Lechien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8767-5179","authenticated-orcid":false,"given":"Antonio","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"7219_CR1","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/lary.27591","volume":"129","author":"JR Lechien","year":"2019","unstructured":"Lechien JR, Saussez S, Schindler A, Karkos PD, Hamdan AL, Harmegnies B, De Marrez LG, Finck C, Journe F, Paesmans M, Vaezi MF (2019) Clinical outcomes of laryngopharyngeal reflux treatment: A systematic review and meta-analysis. Laryngoscope 129:1174\u20131187. https:\/\/doi.org\/10.1002\/lary.27591","journal-title":"Laryngoscope"},{"key":"7219_CR2","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1097\/00005537-200110000-00014","volume":"111","author":"C Hickson","year":"2001","unstructured":"Hickson C, Simpson CB, Falcon R (2001) Laryngeal pseudosulcus as a predictor of laryngopharyngeal reflux. Laryngoscope 111:1742\u20131745. https:\/\/doi.org\/10.1097\/00005537-200110000-00014","journal-title":"Laryngoscope"},{"key":"7219_CR3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1053\/j.gastro.2007.08.047","volume":"133","author":"GW Falk","year":"2007","unstructured":"Falk GW (2007) Laryngopharyngeal reflux: beauty is in the eye of the beholder. Gastroenterology 133:1379\u20131381. https:\/\/doi.org\/10.1053\/j.gastro.2007.08.047","journal-title":"Gastroenterology"},{"key":"7219_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/coa.13140","volume":"43","author":"JR Lechien","year":"2018","unstructured":"Lechien JR, Finck C, Khalife M, Huet K, Delvaux V, Picalugga M, Harmegnies B, Saussez S (2018) Change of signs, symptoms and voice quality evaluations throughout a 3- to 6-month empirical treatment for laryngopharyngeal reflux disease. Clin Otolaryngol 43:1273\u20131282. https:\/\/doi.org\/10.1111\/coa.13140 (Epub 2018 Jun 5)","journal-title":"Clin Otolaryngol"},{"key":"7219_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/ajg.2013.69","volume":"108","author":"DO Francis","year":"2013","unstructured":"Francis DO, Rymer JA, Slaughter JC, Choksi Y, Jiramongkolchai P, Ogbeide E, Tran C, Goutte M, Garrett CG, Hagaman D, Vaezi MF (2013) High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol 108:905\u2013911. https:\/\/doi.org\/10.1038\/ajg.2013.69","journal-title":"Am J Gastroenterol"},{"key":"7219_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1067\/mhn.2002.125760","volume":"127","author":"JA Koufman","year":"2002","unstructured":"Koufman JA, Aviv JE, Casiano RR, Shaw GY (2002) Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg 127:32\u201335. https:\/\/doi.org\/10.1067\/mhn.2002.125760","journal-title":"Otolaryngol Head Neck Surg"},{"key":"7219_CR7","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1097\/MLG.0b013e3181651c3a","volume":"118","author":"BJ Jin","year":"2008","unstructured":"Jin BJ, Lee YS, Jeong SW, Jeong JH, Lee SH, Tae K (2008) Change of acoustic parameters before and after treatment in laryngopharyngeal reflux patients. Laryngoscope 118:938\u2013941. https:\/\/doi.org\/10.1097\/MLG.0b013e3181651c3a","journal-title":"Laryngoscope"},{"key":"7219_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0003489416686586","volume":"126","author":"LM Akst","year":"2017","unstructured":"Akst LM, Haque OJ, Clarke JO, Hillel AT, Best SR, Altman KW (2017) The changing impact of gastroesophageal reflux disease in clinical practice. Ann Otol Rhinol Laryngol 126:229\u2013235","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"7219_CR9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1177\/0194599819827488","volume":"160","author":"JR Lechien","year":"2019","unstructured":"Lechien JR, Akst LM, Hamdan AL, Schindler A, Karkos PD, Barillari MR, Calvo-Henriquez C, Crevier-Buchman L, Finck C, Eun YG, Saussez S, Vaezi MF (2019) Evaluation and management of laryngopharyngeal reflux disease: state of the art review. Otolaryngol Head Neck Surg 160:762\u2013782. https:\/\/doi.org\/10.1177\/0194599819827488","journal-title":"Otolaryngol Head Neck Surg"},{"key":"7219_CR10","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X20165149","volume":"49","author":"C Liu","year":"2016","unstructured":"Liu C, Wang H, Liu K (2016) Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux. Braz J Med Biol Res 49:e5149. https:\/\/doi.org\/10.1590\/1414-431X20165149","journal-title":"Braz J Med Biol Res"},{"key":"7219_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/s0892-1997(02)00097-8","volume":"16","author":"PC Belafsky","year":"2002","unstructured":"Belafsky PC, Postma GN, Koufamn JA (2002) Validity and reliability of the reflux symptom index (RSI). J Voice 16:274\u2013277. https:\/\/doi.org\/10.1016\/s0892-1997(02)00097-8","journal-title":"J Voice"},{"key":"7219_CR12","doi-asserted-by":"publisher","unstructured":"Wei C (2016) A meta-analysis for the role of proton pump inhibitor therapy in patients with laryngopharyngeal reflux.Eur Arch Otorhinolaryngol 273:3795\u20133801. doi: https:\/\/doi.org\/10.1007\/s00405-016-4142-y.","DOI":"10.1007\/s00405-016-4142-y"},{"key":"7219_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1742-1241.2012.02921.x","volume":"66","author":"JJ Heidelbaugh","year":"2012","unstructured":"Heidelbaugh JJ, Metz DC, Yang YX (2012) Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? J Clinc Pract 66:582\u2013591. https:\/\/doi.org\/10.1111\/j.1742-1241.2012.02921.x","journal-title":"J Clinc Pract"},{"key":"7219_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamainternmed.2015.7927","volume":"176","author":"AJ Schoenfeld","year":"2016","unstructured":"Schoenfeld AJ, Grady D (2016) Adverse effects associated with proton pump inhibitors. JAMA Intern Med 176:172\u2013174. https:\/\/doi.org\/10.1001\/jamainternmed.2015.7927","journal-title":"JAMA Intern Med"},{"key":"7219_CR15","doi-asserted-by":"publisher","first-page":"204209861880992","DOI":"10.1177\/2042098618809927","volume":"10","author":"M Jaynes","year":"2019","unstructured":"Jaynes M, Kumar AB (2019) The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf 10:2042098618809927. https:\/\/doi.org\/10.1177\/2042098618809927","journal-title":"Ther Adv Drug Saf"},{"key":"7219_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00405-008-0708-7","volume":"266","author":"JA McGlashan","year":"2009","unstructured":"McGlashan JA, Johnstone LM, Sykes J, Strugala V, Dettmar PW (2009) The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol 266:243\u2013251. https:\/\/doi.org\/10.1007\/s00405-008-0708-7","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"7219_CR17","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/lary.27111","volume":"128","author":"WH Tseng","year":"2018","unstructured":"Tseng WH, Tseng PH, Wu JF, Hsu YC, Lee TY, Ni YH, Wang HP, Hsiao TY, Hsu WC (2018) Double-blind, placebo-controlled study with alginate suspension for laryngopharyngeal reflux disease. Laryngoscope 128:2252\u20132260. https:\/\/doi.org\/10.1002\/lary.27111","journal-title":"Laryngoscope"},{"key":"7219_CR18","doi-asserted-by":"publisher","unstructured":"Wilkie MD, Fraser HM, Raja H (2018) Gaviscon\u00ae Advance alone versus co-prescription of Gaviscon\u00ae Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux.Eur Arch Otorhinolaryngol 275:2515\u20132521. doi: https:\/\/doi.org\/10.1007\/s00405-018-5079-0.","DOI":"10.1007\/s00405-018-5079-0"},{"key":"7219_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1741-7015-8-18","volume":"8","author":"Schulz KF, Altman DG, Moher D; CONSORT Group","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D; CONSORT Group (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 8:18. https:\/\/doi.org\/10.1186\/1741-7015-8-18","journal-title":"BMC Med"},{"key":"7219_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jvoice.2008.08.008","volume":"24","author":"A Schindler","year":"2020","unstructured":"Schindler A, Mozzanica F, Ginocchio D, Peri A, Bottero A, Ottaviani F (2020) Reliability and Clinical Validity of the Italian Reflux Symptom Index. J Voice 24:354\u2013358. https:\/\/doi.org\/10.1016\/j.jvoice.2008.08.008","journal-title":"J Voice"},{"key":"7219_CR21","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1097\/00005537-200108000-00001","volume":"111","author":"PC Belafsky","year":"2001","unstructured":"Belafsky PC, POstma GN, Koufman JA, (2001) The validity and reliability of the Reflux Finding Score (RFS). Laryngoscope 111:1313\u20131317. https:\/\/doi.org\/10.1097\/00005537-200108000-00001","journal-title":"Laryngoscope"},{"key":"7219_CR22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"Katz PO, Gerson LB, Vela MF (2013) Guidelines for the diagnosis and management of gastroesophageal refl ux disease. Am J Gastroenterol 108:308\u2013328. https:\/\/doi.org\/10.1038\/ajg.2012.444","journal-title":"Am J Gastroenterol"},{"key":"7219_CR23","unstructured":"ICH Harmonised Tripartite Guideline. Statistical Principles for Clinical Trials. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E9\/Step4\/E9_Guideline.pdf Accessed 24 June 2021."},{"key":"7219_CR24","volume-title":"Adherence to long-term therapies: evidence for action","author":"World Health Organization","year":"2003","unstructured":"World Health Organization (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva"},{"key":"7219_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.otohns.2008.06.003","volume":"139","author":"O Reichel","year":"2008","unstructured":"Reichel O, Dressel H, Wiederanders K, Issing WJ (2008) Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. Otolaryngol Head Neck Surg 139:414\u2013420. https:\/\/doi.org\/10.1016\/j.otohns.2008.06.003","journal-title":"Otolaryngol Head Neck Surg"},{"key":"7219_CR26","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1097\/00005537-200112000-00013","volume":"111","author":"JP Noordzij","year":"2001","unstructured":"Noordzij JP, Khidr A, Evans BA, Desper E, Mittal RK, Reibel JF, Levine PA (2001) Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngoscope 111:2147\u20132151. https:\/\/doi.org\/10.1097\/00005537-200112000-00013","journal-title":"Laryngoscope"},{"key":"7219_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.otohns.2004.03.037","volume":"131","author":"DL Steward","year":"2004","unstructured":"Steward DL, Wilson KM, Kelly DH, Patil MS, Schwartzbauer HR, Long JD, Welge JA (2004) Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg 131:342\u2013350. https:\/\/doi.org\/10.1016\/j.otohns.2004.03.037","journal-title":"Otolaryngol Head Neck Surg"},{"key":"7219_CR28","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1111\/j.1572-0241.2006.00693.x","volume":"101","author":"JM Wo","year":"2006","unstructured":"Wo JM, Koopman J, Harrell SP, Parker K, Winstead W, Lentsch E (2006) Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. Am J Gastroenterol 101:1972\u20131978. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00693.x","journal-title":"Am J Gastroenterol"},{"key":"7219_CR29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/00365520310001860","volume":"38","author":"AJ Eherer","year":"2003","unstructured":"Eherer AJ, Habermann W, Hammer HF, Kiesler K, Friedrich G, Krejs GJ (2003) Effect of pantoprazole on the course of reflux associated laryngitis: a placebo-controlled double-blind crossover study. Scand J Gastroenterol 38:462\u2013467. https:\/\/doi.org\/10.1080\/00365520310001860","journal-title":"Scand J Gastroenterol"},{"key":"7219_CR30","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/00005537-200106000-00009","volume":"111","author":"PC Belafsky","year":"2001","unstructured":"Belafsky PC, Postma GN, Koufman JA (2001) Laryngopharyngeal reflux symptoms improve before changes in physical findings. Laryngoscope 111:979\u2013981. https:\/\/doi.org\/10.1097\/00005537-200106000-00009","journal-title":"Laryngoscope"},{"key":"7219_CR31","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1080\/03639040701385691","volume":"33","author":"CJ Kapadia","year":"2007","unstructured":"Kapadia CJ, Mane VB (2007) Raft-forming agents: antireflux formulations. Drug Develop Indust Pharm 33:1350\u20131361. https:\/\/doi.org\/10.1080\/03639040701385691","journal-title":"Drug Develop Indust Pharm"},{"key":"7219_CR32","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1211\/jpp\/61.08.0005","volume":"61","author":"V Strugala","year":"2009","unstructured":"Strugala V, Avis J, Jolliffe IG, Johnstone LM, Dettman PW (2009) The role of an alginate suspension on pepsin and bile-acides-key agressirs in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease? J Pharm Pharmacol 61:1021\u20131028. https:\/\/doi.org\/10.1211\/jpp\/61.08.0005","journal-title":"J Pharm Pharmacol"},{"key":"7219_CR33","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/gut.2009.192922","volume":"59","author":"KEL Mc Coll","year":"2010","unstructured":"Mc Coll KEL, Clarke A, Seenan J (2010) Acid pocket, hiatus harniea and acid reflux. Gut 59:430\u2013431. https:\/\/doi.org\/10.1136\/gut.2009.192922","journal-title":"Gut"},{"key":"7219_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2036.2011.04678.x","volume":"34","author":"MA Kwiatek","year":"2011","unstructured":"Kwiatek MA, Roman S, Fareeduddin A, Pandolfino JE, Kharilas PJ (2011) An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial acid pocket in symptomatic GERD patients. Aliment Pharmacol Therap 34:59\u201366. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04678.x","journal-title":"Aliment Pharmacol Therap"},{"key":"7219_CR35","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.3748\/wjg.v18.i32.4371","volume":"18","author":"E Savarino","year":"2012","unstructured":"Savarino E, de Bortoli N, Zentilin P, Martinucci I, Bruzzone L, Furnari M, Marchi S, Savarino V (2012) Alginate controls heartburn in patients with erosive and nonerosive reflux disease. World J Gastroenterol 18:4371\u20134378. https:\/\/doi.org\/10.3748\/wjg.v18.i32.4371","journal-title":"World J Gastroenterol"},{"key":"7219_CR36","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/ajg.2013.132","volume":"108","author":"PJ Kahrilas","year":"2013","unstructured":"Kahrilas PJ, McColl K, Fox M, O\u2019Rourke L, Sifrim D, Smout AJ, Boeckxstaens G (2013) The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol 108:1058\u20131064. https:\/\/doi.org\/10.1038\/ajg.2013.132","journal-title":"Am J Gastroenterol"},{"key":"7219_CR37","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/apt.12318","volume":"37","author":"R Sweis","year":"2013","unstructured":"Sweis R, Kaufman E, Anggiansah A, Wong T, Dettmar P, Fried M, Schwizer W, Avvari RK, Pal A, Fox M (2013) Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients. Aliment Pharmacol Ther 37:1093\u20131102. https:\/\/doi.org\/10.1111\/apt.12318","journal-title":"Aliment Pharmacol Ther"},{"key":"7219_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/apt.12640","volume":"39","author":"E Thomas","year":"2014","unstructured":"Thomas E, Wade A, Crawford G, Jenner B, Levinson N, Wilkinson J (2014) Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 39:595\u2013602. https:\/\/doi.org\/10.1111\/apt.12640","journal-title":"Aliment Pharmacol Ther"},{"key":"7219_CR39","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/s11605-012-1866-x","volume":"16","author":"V Becker","year":"2012","unstructured":"Becker V, Graf S, Schlag C, Schuster T, Feussner H, Schmid RM, Bajbouj M (2012) First agreement analysis and day-to-day comparison of pharyngeal pH monitoring with pH\/impedance monitoring in patients with suspected laryngopharyngeal reflux. J Gastrointest Surg 16:1096\u20131101. https:\/\/doi.org\/10.1007\/s11605-012-1866-x","journal-title":"J Gastrointest Surg"},{"key":"7219_CR40","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/apt.12482","volume":"38","author":"CT Chiu","year":"2013","unstructured":"Chiu CT, Hsu CM, Wang CC, Chang JJ, Sung CM, Lin CJ, Chen LW, Su MY, Chen TH (2013) Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther 38:1054\u20131064","journal-title":"Aliment Pharmacol Ther"},{"key":"7219_CR41","doi-asserted-by":"crossref","unstructured":"Pouchain D, Bigard MA, Liard F, Childs M, Decaudin A, McVey D (2012) Gaviscon\u00ae vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol 12:18.","DOI":"10.1186\/1471-230X-12-18"},{"key":"7219_CR42","doi-asserted-by":"publisher","first-page":"642","DOI":"10.5009\/gnl18378","volume":"13","author":"JH Kim","year":"2019","unstructured":"Kim JH, Lee YC, Kim EH, Park JC, Shin SK, Lee SK, Jung DH, Park JJ, Youn YH, Park H (2019) The clinical efficacy of a pure alginate formulation (Lamina G) for controlling symptoms in individuals with reflux symptoms: a randomized clinical study. Gut Liver 13:642\u2013648","journal-title":"Gut Liver"},{"key":"7219_CR43","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/coa.13395","volume":"44","author":"JR Lechien","year":"2019","unstructured":"Lechien JR, Muls V, Dapri G, Mouawad F, Eisendrath P, Schindler A, Nacci A, Barillari MR, Finck C, Saussez S, Akst LM, Sataloff RT (2019) The management of suspected or confirmed laryngopharyngeal reflux patients with recalcitrant symptoms: A contemporary review. Clin Otolaryngol 44:784\u2013800. https:\/\/doi.org\/10.1111\/coa.13395","journal-title":"Clin Otolaryngol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-021-07219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-021-07219-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-021-07219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T04:12:07Z","timestamp":1649218327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-021-07219-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["7219"],"URL":"https:\/\/doi.org\/10.1007\/s00405-021-07219-0","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"23 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have nothing to disclose","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Ethics Committee of the University of Milan (approval n.2017\/ST\/068).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent to participate to the study","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}